|
|
Suppliers for
Ethaselen
|
Properties | CAS |
217798-39-5 |
|
2 Registered suppliers
Description : Ethaselen, also known as BBSKE, is a novel organoselenium thioredoxin reductase inhibitor, is currently being investigated in a phase I clinical trial in China. Ethaselen enhanced the efficacy of radiation therapy both in vivo and in vitro without observable toxicity. BBSKE was found to suppress irradiation-induced activation dramatically when using A549 cells stably transfected with luciferase reporter. Ethaselen is a potentially promising agent for the treatment of patients with NSCLC clinically. - Molecular Weight :422.199
Molecular Formula : C16H12N2O2Se2 Canonical SMILES : C1=CC=C2C(=C1)C(=O)N([Se]2)CCN3C(=O)C4=CC=CC=C4[Se]3 InChI : InChI=1S/C16H12N2O2Se2/c19-15-11-5-1-3-7-13(11)21-17(15)9-10-18-16(20)12-6-2-4-8-14(12)22-18/h1-8H,9-10H2 InChIKey : SFFSGPCYJCMDJM-UHFFFAOYSA-N Appearance : white solid powder Synonyms : 1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)]ethane; BBSKE
More details are to be found here
Detailed information on the suppliers of
Ethaselen
|
Properties:
... more properties and specification on Ethaselen
|
|
Privileged suppliers
Last update 2024-04-29
|